Published in Am J Transplant on December 01, 2005
Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol (2010) 2.69
How I treat EBV lymphoproliferation. Blood (2009) 2.18
Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★). Am J Transplant (2011) 1.04
Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation (2008) 0.95
Comparative pathobiology of macaque lymphocryptoviruses. Comp Med (2008) 0.93
Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation. Immunotherapy (2010) 0.84
Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report. Am J Transplant (2012) 0.84
Posttransplant lymphoproliferative disease after pediatric solid organ transplantation. Clin Dev Immunol (2013) 0.83
Therapeutic options in post-transplant lymphoproliferative disorders. Ther Adv Hematol (2011) 0.81
Posttransplant lymphoproliferative disease after lung transplantation. Clin Dev Immunol (2013) 0.80
Successful treatment of central nervous system PTLD with rituximab and cranial radiotherapy. Pediatr Nephrol (2013) 0.78
Small intestine transplantation today. Langenbecks Arch Surg (2007) 0.77
Post-transplantation lymphoproliferative disorder in living-donor liver transplantation: a single-center experience. Surg Today (2012) 0.77
Fcγ-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder. J Immunol Res (2014) 0.76
Outcome of rapamycin therapy for post-transplant-lymphoproliferative disorder after kidney transplantation: case series. Int J Hematol Oncol Stem Cell Res (2015) 0.76
A 47-year-old stem cell transplant recipient with fever, cough and chest pain. Can Respir J (2015) 0.75
Chemoimmunotherapy and withdrawal of immunosuppression for monomorphic posttransplant lymphoproliferative disorders. Clin Lymphoma Myeloma Leuk (2013) 0.75
Early focal segmental glomerulosclerosis as a cause of renal allograft primary nonfunction. Case Rep Transplant (2013) 0.75
Treatment of post-transplantation lymphoproliferative disorders after kidney transplant with rituximab and conversion to m-TOR inhibitor. Colomb Med (Cali) (2016) 0.75
Post-transplant lymphoproliferative disorder presenting with skin ulceration in a renal transplant recipient who achieved sustained remission with rituximab therapy: A case report. Mol Clin Oncol (2016) 0.75
Posttransplant lymphoproliferative disorders following liver transplantation: Where are we now? World J Gastroenterol (2015) 0.75
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature (1999) 5.76
A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection. Proc Natl Acad Sci U S A (1984) 5.60
CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature (1998) 5.21
Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med (1997) 5.19
Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site. Proc Natl Acad Sci U S A (1986) 5.12
Epstein-Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping. Proc Natl Acad Sci U S A (1980) 5.02
Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood (1997) 4.36
Epstein-Barr virus RNA. VIII. Viral RNA in permissively infected B95-8 cells. J Virol (1982) 3.26
Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest (1997) 3.22
Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell (1992) 3.21
Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies. J Virol (1983) 3.06
Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes (1999) 3.00
Extended resections for hilar cholangiocarcinoma. Ann Surg (1999) 2.93
Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med (1997) 2.88
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res (1996) 2.86
Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci U S A (1991) 2.82
Lymphoproliferative lesions of the ocular adnexa. Analysis of 112 cases. Ophthalmology (1998) 2.60
Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med (1997) 2.59
T-cell epitope mapping by flow cytometry. Nat Med (1998) 2.56
Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol (1999) 2.55
A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol (1996) 2.34
Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer (1997) 2.30
Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol (2000) 2.29
Mapping of polypeptides encoded by the Epstein-Barr virus genome in productive infection. Proc Natl Acad Sci U S A (1982) 2.20
RNA encoded by the IR1-U2 region of Epstein-Barr virus DNA in latently infected, growth-transformed cells. J Virol (1983) 2.12
Pattern of month of birth in diabetic and non-diabetic adults. Isr Med Assoc J (2002) 2.03
Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann Hematol (2003) 2.01
Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J Clin Invest (1996) 2.00
Monocyte deactivation--rationale for a new therapeutic strategy in sepsis. Intensive Care Med (1996) 2.00
A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation (1998) 1.97
Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjögren's syndrome. J Clin Invest (1998) 1.92
Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia (2006) 1.88
Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant (2012) 1.88
Induction of p21CIP/WAF-1 and G2 arrest by ionizing irradiation impedes caspase-3-mediated apoptosis in human carcinoma cells. Oncogene (2006) 1.86
High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood (1996) 1.82
Isolation of viruses from specimens submitted for direct immunofluorescence test for respiratory syncytial virus. J Pediatr (1986) 1.78
Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia (2013) 1.77
The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma. J Pathol (2000) 1.76
CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol (1987) 1.76
An Epstein-Barr virus DNA fragment encodes messages for the two major envelope glycoproteins (gp350/300 and gp220/200). J Virol (1984) 1.76
The biology and chemistry of Epstein-Barr virus. J Infect Dis (1982) 1.74
Expression of Epstein-Barr virus-gene products in Burkitt's lymphoma in Northeast Brazil. Blood (1996) 1.74
Clinical aspects: from systemic inflammation to 'immunoparalysis'. Chem Immunol (2000) 1.73
Switch region content of hybridomas: the two spleen cell Igh loci tend to rearrange to the same isotype. J Immunol (1987) 1.73
Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia (2006) 1.72
LI-cadherin: a marker of gastric metaplasia and neoplasia. Gut (2001) 1.72
Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene (1999) 1.71
Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol (1998) 1.68
Apoptosis: implications of basic research for clinical oncology. Lancet Oncol (2001) 1.68
T-cell and T/natural killer-cell lymphomas involving ocular and ocular adnexal tissues: a clinicopathologic, immunohistochemical, and molecular study of seven cases. Ophthalmology (1999) 1.66
Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation (1997) 1.64
Systemic inflammation in patients with heart failure. Eur Heart J (1998) 1.64
HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J Immunol (1986) 1.63
Distribution of human CMV-specific memory T cells among the CD8pos. subsets defined by CD57, CD27, and CD45 isoforms. Eur J Immunol (1999) 1.62
Cellular localization of latent murine cytomegalovirus. J Virol (1998) 1.62
Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. Leukemia (2006) 1.62
Chemotherapy in alveolar soft part sarcomas. What do we know? Eur J Cancer (2003) 1.60
EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia (2012) 1.60
Exhaled nitric oxide in childhood asthma. Eur J Pediatr (1996) 1.57
HLA type-independent method to monitor polyoma BK virus-specific CD4 and CD8 T-cell immunity. Am J Transplant (2006) 1.56
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood (2000) 1.55
High incidence of Epstein-Barr virus genomes in Hodgkin's disease. Am J Pathol (1990) 1.54
Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant (2013) 1.54
A theoretical approach to the question of "community control" of health services facilities. Am J Public Health (1971) 1.54
Monokine expression in Langerhans' cell histiocytosis and sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) J Pathol (1996) 1.53
Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurology (2009) 1.53
Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood (1999) 1.53
Apoptosis-induced cleavage of beta-catenin by caspase-3 results in proteolytic fragments with reduced transactivation potential. J Biol Chem (2000) 1.50
Electron-beam computed tomography in the assessment of coronary artery disease after heart transplantation. Circulation (2000) 1.47
Current characteristics and outcome of cytomegalovirus infections after kidney transplantation. Transpl Infect Dis (2014) 1.46
Magnetic resonance imaging including magnetic resonance cholangiopancreatography for tumor localization and therapy planning in malignant hilar obstructions. Acta Radiol (2005) 1.46
Towards a better definition of human leucocyte surface molecules. Immunol Today (1989) 1.42
[Participation and support of clinical studies and other scientific investigations. Statement of the German Society for Pathology]. Pathologe (2013) 1.42
Discontinuation of antistreptococcal prophylaxis. A double-blind study in rheumatic patients free of heart disease. JAMA (1966) 1.42
Long-acting somatostatin analog controls acid and gastrin secretion in benign, not in malignant, Zollinger-Ellison syndrome. J Clin Gastroenterol (1989) 1.41
The E8E2C protein, a negative regulator of viral transcription and replication, is required for extrachromosomal maintenance of human papillomavirus type 31 in keratinocytes. J Virol (2000) 1.40
Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut (2009) 1.40
Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol (1999) 1.40
[Antimicrobial therapy in neutropenia]. Dtsch Med Wochenschr (1997) 1.40
APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur J Immunol (1993) 1.39
Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma. Cell Death Differ (2006) 1.39
Virostatic therapy for advanced lymphoproliferation associated with the Epstein-Barr virus in an HIV-infected patient. N Engl J Med (2000) 1.39
[Simulation of a colon carcinoma: diuretic-induced ulcerative-stricturing ischemic colitis]. Dtsch Med Wochenschr (2004) 1.39
[Non-invasive monitoring of rejection after cardiac transplantation. The method and retrospective analysis of data on 734 patients]. Dtsch Med Wochenschr (2001) 1.39
On homelessness and the American way. Am J Public Health (1986) 1.38
[Project graph technique for time management in abdominal ultrasound evaluations]. Ultraschall Med (1999) 1.38